CAR T-Cell Therapy Pushes Grandmother’s Multiple Myeloma Into Long Remission

As head of a family that includes seven children and 12 grandchildren, Susan Voigt says she is used to putting other people first. When it comes to trailblazing multiple myeloma treatment, however, she is proudly out in front. A longtime Vermont resident, Voigt, 69, was the first person from her state to receive CAR T-cell … Read more

What is Richter’s Syndrome and How is it Treated?

Richter’s syndrome involves the rapid transformation of chronic lymphocytic leukemia (CLL) into a significantly more aggressive form of lymphoma, usually diffuse large B-cell lymphoma (DLBCL), but occasionally Hodgkin lymphoma (HL). It arises in 2-10% of all patients with CLL and can occur at any time in the course of the disease. The goal of treatment … Read more

What are Indolent Lymphomas and How Are They Treated?

Indolent lymphomas are types of non-Hodgkin lymphoma (NHL) that grow and spread slowly. They account for about 40% of all NHL cases in the United States and generally arise later in life. Treatment for indolent lymphomas depends on a variety of factors, including the type and stage of the disease (how far it has advanced). … Read more

Signs and Symptoms of Blood Cancers

Blood cancers (or hematologic cancers) are diseases that originate in blood-forming tissue such as the bone marrow or cells within in the immune system. There are three main types of blood cancers: Leukemia: cancer that originates in the body’s blood-forming tissues, such as the bone marrow. The disease causes large numbers of myeloid blood cells … Read more

Acute Leukemia Diagnosis: What to Know and Expect

Treatment for acute forms of adult leukemia has advanced markedly since the days when all patients generally received the same course of treatment. A patient’s age and overall health, the type of leukemia he or she has, and the goal of therapy all influence the treatment plan. What are the types of acute leukemia? There … Read more

Venetoclax Combination Approved for Older Patients with AML

The U.S. Food and Drug Administration (FDA) approved a novel targeted drug to treat acute myelogenous leukemia (AML) in older patients, a segment of the blood cancer population in dire need of improved therapies. In a phase 3 clinical trial, researchers showed that the oral drug, venetoclax (or Venclexta), when given along with azacitidine, could … Read more

Hodgkin Lymphoma Treatment Has Been Transformed by Immunotherapy. New Study Helps Explain Why

The go-to metaphor for cancer drugs known as immune checkpoint inhibitors is a brake-release lever — a means of setting loose an immune system attack on tumor cells. Helpful as it is, the analogy glosses over a highly complex mechanism involving multiple types of immune cells, cell receptors, signals, and responses — so intricate that … Read more

New Drug Regimens Show Promise in Early and Late Myeloma

Treatment advances for multiple myeloma continue to bring improved outcomes for patients in different stages of their disease. Recent clinical trial reports show progress in treating two myeloma populations — newly diagnosed, transplant eligible patients, and individuals whose disease has progressed following several lines of therapy. In one trial, the phase 2 GRIFFIN study showed … Read more

Wave of New Therapies Improve Outcomes for Patients with Multiple Myeloma

For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and tested by Dana-Farber scientists have gained approval from the U.S. Food and Drug Administration (FDA) or taken a step toward approval after posting solid results … Read more

Cancer Patient Faces Multiple Diagnoses with the Strength of a Warrior

One bout of cancer is enough to contend with, but since 2014 Mary Johnson has had to cope with four different cancers and related conditions. Despite these tests of her physical and emotional strength, Johnson is doing well today after treatment at Dana-Farber. “Coming to Dana-Farber gave me confidence because they supported me, and I … Read more

‘Watchful Waiting’ for Lymphoma: What You Need to Know

If you’ve been diagnosed with slow-growing lymphoma but don’t have any symptoms of the disease, your doctor is likely to recommend monitoring the disease closely but not treating it until symptoms appear — an approach known as watchful waiting. This advice might seem to run counter to the standard recommendation that cancer be treated at … Read more

Approval of Myeloma Drug Improves Patients’ Prospects

Five years into his treatment for multiple myeloma, Mark Young was attending a Dana-Farber conference to learn about the latest research in the disease when his oncologist — Paul Richardson, MD, clinical program leader and director of clinical research at the Institute’s Jerome Lipper Multiple Myeloma Center — came running up with some timely news. … Read more

Transplant Program Milestone is Patient’s First Step in Returning to the Dance Floor

The first time Bill Cronin Googled his own cancer diagnosis in 2016, his heart sank. He had Sézary syndrome, a rare and aggressive form of cutaneous T-cell lymphoma  — and staring back at him were countless articles predicting a negative prognosis. However, after receiving a stem-cell transplant at Dana-Farber/Brigham and Women’s Cancer Center, Cronin is … Read more